pSivida and Nicox have signed a collaboration agreement to explore the use of pSivida’s bioerodible sustained release drug delivery system with Nicox’s nitric oxide-donating compounds to develop an IOP-lowering drug, according to a press release.
Under the agreement, pSivida will be responsible for initial development of ocular insert formulations and the two companies will collaborate on selecting the product candidates from Nicox’s research portfolio to combine with the sustained release technology.
Nicox will pay pSivida an undisclosed amount for the ocular insert
Uncategorized